AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...

AstraZeneca PLC AZN announced that the FDA has approved an expanded use of its breast cancer drug, Truqap (capivasertib), for ...

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

The FDA has approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for men with phosphatase and tensin homolog (PTEN)-deficient metastatic androgen pathway ...

The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...

AstraZeneca’s Truqap (capivasertib) gained FDA approval, combined with abiraterone and prednisone, for treatment of certain ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

AstraZeneca (AZN) stock is in focus as the FDA approves a label expansion for its breast cancer therapy Truqap in prostate ...

AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...

AstraZeneca's drug Truqap in combination with two other medications secured approval for the treatment of a form of advanced prostate cancer by the Food and Drug Administration. Approval was based on ...

MEDSIR, a leading international oncology research company, has presented the final results of the ZZ‑FIRST study during an oral session at the ASCO 2026 scientific congress, held in Chicago. This ...

RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAPIn prostate cancer, PTEN protein loss is a ...